WO2023172872A3 - Biomarkers for combination therapies - Google Patents

Biomarkers for combination therapies Download PDF

Info

Publication number
WO2023172872A3
WO2023172872A3 PCT/US2023/063788 US2023063788W WO2023172872A3 WO 2023172872 A3 WO2023172872 A3 WO 2023172872A3 US 2023063788 W US2023063788 W US 2023063788W WO 2023172872 A3 WO2023172872 A3 WO 2023172872A3
Authority
WO
WIPO (PCT)
Prior art keywords
subject
biomarkers
combination therapies
mutation
cancer
Prior art date
Application number
PCT/US2023/063788
Other languages
French (fr)
Other versions
WO2023172872A2 (en
Inventor
Peter J.P. CROUCHER
Maya RIDINGER
Mark Erlander
Errin SAMUELSZ
Original Assignee
Cardiff Oncology, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiff Oncology, Inc. filed Critical Cardiff Oncology, Inc.
Publication of WO2023172872A2 publication Critical patent/WO2023172872A2/en
Publication of WO2023172872A3 publication Critical patent/WO2023172872A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed herein include methods, compositions, and kits suitable for use in treating a subject having cancer and/or determining the efficacy of treatment to a subject having a cancer. In some embodiments, the method comprises determining the presence or absence of at least one mutation in a gene encoding mechanistic target of rapamycin kinase (mTOR) in the subject; and administering onvansertib and an antiandrogen or androgen antagonist to the subject, if the at least one mutation in the mTOR gene is determined to be present in the subject.
PCT/US2023/063788 2022-03-07 2023-03-06 Biomarkers for combination therapies WO2023172872A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263317277P 2022-03-07 2022-03-07
US63/317,277 2022-03-07

Publications (2)

Publication Number Publication Date
WO2023172872A2 WO2023172872A2 (en) 2023-09-14
WO2023172872A3 true WO2023172872A3 (en) 2023-11-02

Family

ID=87935892

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/063788 WO2023172872A2 (en) 2022-03-07 2023-03-06 Biomarkers for combination therapies

Country Status (1)

Country Link
WO (1) WO2023172872A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020198281A1 (en) * 2019-03-28 2020-10-01 Cardiff Oncology, Inc. Plk1 inhibitors and psa levels in prostate cancer
WO2021155073A1 (en) * 2020-01-29 2021-08-05 Cardiff Oncology, Inc. Treatment of leukemias and lymphomas with combinations of bcl-2 inhibitors and plk1 inhibitors
WO2021173731A1 (en) * 2020-02-25 2021-09-02 University Of Tennessee Research Foundation Selective androgen receptor covalent antagonists (sarcas) and methods of use thereof
WO2021226403A1 (en) * 2020-05-08 2021-11-11 Cardiff Oncology, Inc. Methods of monitoring kras mutations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020198281A1 (en) * 2019-03-28 2020-10-01 Cardiff Oncology, Inc. Plk1 inhibitors and psa levels in prostate cancer
WO2021155073A1 (en) * 2020-01-29 2021-08-05 Cardiff Oncology, Inc. Treatment of leukemias and lymphomas with combinations of bcl-2 inhibitors and plk1 inhibitors
WO2021173731A1 (en) * 2020-02-25 2021-09-02 University Of Tennessee Research Foundation Selective androgen receptor covalent antagonists (sarcas) and methods of use thereof
WO2021226403A1 (en) * 2020-05-08 2021-11-11 Cardiff Oncology, Inc. Methods of monitoring kras mutations

Also Published As

Publication number Publication date
WO2023172872A2 (en) 2023-09-14

Similar Documents

Publication Publication Date Title
WO2020093006A8 (en) Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7)
Tougeron et al. Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study
Upadhyay et al. Risk and impact of radiation related lymphopenia in lung cancer: A systematic review and meta-analysis
EP4012415A3 (en) Methods and compositions related to toxicity associated with cell therapy
Fujita et al. Carbon‐ion radiation enhances migration ability and invasiveness of the pancreatic cancer cell, PANC‐1, in vitro
Yu et al. DAB2IP regulates autophagy in prostate cancer in response to combined treatment of radiation and a DNA-PKcs inhibitor
Zhang et al. Down-regulation of G9a triggers DNA damage response and inhibits colorectal cancer cells proliferation
Feng et al. Targeted radiosensitization with PARP1 inhibition: optimization of therapy and identification of biomarkers of response in breast cancer
MX2022006366A (en) Combination therapy involving diaryl macrocyclic compounds.
NO20082683L (en) Neuroendocrine tumor therapy
Goldstein et al. Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?
CA3183032A1 (en) Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
MX2023008968A (en) Cdk2 inhibitors and methods of using the same.
MX2024001248A (en) Combination therapy for treating abnormal cell growth.
Césaire et al. Sensitization of chondrosarcoma cells with PARP inhibitor and high-LET radiation
WO2024026479A3 (en) Cdk2 inhibitors and methods of using the same
WO2024026483A3 (en) Cdk2 inhibitors and methods of using the same
WO2024026484A3 (en) Cdk2 inhibitors and methods of using the same
Bernier et al. Surgery and radiation therapy of triple-negative breast cancers: From biology to clinics
WO2023172872A3 (en) Biomarkers for combination therapies
WO2010030865A3 (en) Loss of fbxw7 is a biomarker of sensitivity to treatment of tumors with inhibitors of mtor
MX2022006500A (en) Combination therapy involving diaryl macrocyclic compounds.
Li et al. Simultaneous targeting of EGFR and mTOR inhibits the growth of colorectal carcinoma cells
Nishiwaki et al. Utility of allogeneic stem cell transplantation for adult Ph+ ALL with complete molecular remission
MX2022008532A (en) Ahr inhibitors and uses thereof.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23767587

Country of ref document: EP

Kind code of ref document: A2